Updated Safety and Efficacy from a Phase 1 Study of RMC-6236, a RAS (ON) Multi-Selective, Tri-Complex Inhibitor, in Patients with RAS Mutant Pancreatic Ductal Adenocarcinoma (PDAC)

B. Wolpin,D. Hong,A. Spira,A. Starodub, W. Park,D. Sommerhalder, J. Valerin,M. Barve, S. Punekar,M. Pelster, B. Herzberg, N. Azad, K. Aung,J. R. Hecht, L. Cheng, R. Vora, Z. Salman, Y. Zhang, T. Lin, I. Garrido-Laguna

EUROPEAN JOURNAL OF CANCER（2024）

Cited 0|Views1

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined